||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Venn Life Share Discussion Threads
Showing 1051 to 1065 of 1075 messages
|Yorgi, what would you call a person who relentlessly "promotes" a company, all the way from the giddy heights of over 12p, through incessant fundraisings, all the pitiful way to 0.1p? Would they be Saints perchance?|
|45 days to go before current cash raising event for Integumen closes. 23.5% of equity on offer to raise £2.1 million cash prior to float.|
|And the selling continues! . The company owes it's shareholders an explanation & now.|
|Only an observation yorgi but you seem to call investors tolls or whatever just because they disagree with your position.
I always welcome both balanced sides to any investment case|
|As I say similar was being said about the progress at CPX this time last year and totally unwarranted comments and criticisms of the BOD, but they can't announce what has not been completed or signed off. Also so often BOD want to make announcements and inform shareholders but it is NOMADS that stop the BOD informing shareholders of progress and directors get blamed. In CPX's case Quadrupling plus in a year has proved expensive for those that thought the share price was right instead of focusing on what we had been told by our BOD.
The silence is concerning I don't deny but has there been anything from anywhere that has suggested that the BOD won't deliver along the line of the expected revenues ?|
|Its not easy to work out if the share price gyrations are just pi's getting excited and then worried and then back again, or whether it actually reflects anything real.
There's not exactly a huge volume when it happens and its been pretty low since last October.|
|Whether wise or not only after the next RNS will that be clear. The falling share price is never encouraging but a year ago some were saying similar about CPX when it was falling and of course trolls joined in posting rubbish. Lack of news does not always mean that all is not well and the BOD sometimes can't release news for reasons that are not always apparent.
So either a good time to buy or well to get out, remains to be seen.|
|That's what's exercising folk - the lack of one so far, so could (should) come any moment. Or not ;-)|
|TU on 8/1/16,,,,,,,should we expect one any day ?|
|The story hasn't changed as far as I'm concerned so I'm happy to wait for news on the IPO and trading. We all know it's coming - good or bad. FWIW I think VENN management are professional and straight.|
|The thing that will make me very grumpy here, is if their semi-forecast in the AGM turns out to be wide of the mark. No way of knowing until the day though.|
|Very good post Yump, all very true in my opinion.|
|Please totally ignore my comments ref redundancies, it was meant for the FRP thread. :-//
Apologies if any distress caused PJ|
|It is always a little worrying when there is silence, particularly with AIM companies, and like everyone else, I would be comforted to hear something. However, as has been pointed out, there is logic in waiting for the Integumen issue to be sorted.
Additionally I note that the house broker, Hybridian, raised their forecasts for 2016 and 2017 on the 8th November. At that stage there would have been high visibility on 2016 - a CRO is hardly dependent on Christmas sales and should know what the staff will be working on over the next few weeks! If the house broker does not have the inside track then I don't know who does.|
|On the positive side, the removal of Integumen does look like it will clarify the main business position and make it easier to see if its progressing well. Can't really argue with the logic; if it had remained, there could potentially always be an issue with figuring out if the losses were clouding the real business, or at worst were being used as an excuse. No excuses from now on. Its removal hasn't done any harm.
It may also be that if the guys in charge are more interested in money than the business, that they are actually more aligned with investors than some that are just enthusiastic about their business.
In June they said:
"Revenues for the 6 months ended 30 June 2016 will exceed EUR8.0m, a considerable increase on the comparative period last year (H1 2015: EUR4.26m). With a strong first half and good visibility on second half revenues, the Board is confident that the Company is on track to deliver full year revenues in excess of EUR16m and to record the Company's first profits at the PBT level, in-line with market expectations, as well as continue to generate free cashflows."
That was without selling Integumen. No doubt there will be exceptionals because of the sale, but the underlying figures should tell whether the idea of PBT was actually valid or not. It may be a small amount, but it should be there, given the confident AGM statement above.|